Compare LAW & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | VNDA |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.9M | 231.0M |
| IPO Year | 2021 | 2005 |
| Metric | LAW | VNDA |
|---|---|---|
| Price | $5.72 | $3.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $11.50 |
| AVG Volume (30 Days) | 291.8K | ★ 1.2M |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $156,849,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $12.74 | $12.05 |
| Revenue Next Year | $10.55 | $30.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.29 | ★ 8.72 |
| 52 Week Low | $2.45 | $3.57 |
| 52 Week High | $9.11 | $9.91 |
| Indicator | LAW | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 36.09 |
| Support Level | $3.49 | $3.57 |
| Resistance Level | $6.39 | $5.49 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 44.97 | 14.29 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.